Clinical trials
Antibody clinical trials
Below are recruiting antibody clinical trials, each written for real people, not researchers. We’re tracking 539 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06014658RecruitingPhase 1/Phase 2
Study of MBRC-101 for advanced solid tumors
This trial tests a new drug, MBRC-101, that targets a protein called EphA5 found on some cancer cells. It is for people with advanced solid tumors (like lung, breast, or pancreatic cancer) that have stopped responding to other treatments. The study aims to find a safe dose and see if the drug can shrink tumors.
San Francisco, CaliforniaAges 18 years+ - NCT06041516RecruitingPhase 1
New drug ADCT-701 for neuroendocrine and nerve tumors
This trial tests a new drug called ADCT-701 for people with certain rare cancers (neuroendocrine tumors, adrenal cancer, or a type of nerve tumor) that have come back or spread. The drug is an antibody-drug conjugate, which works like a targeted missile to kill cancer cells while trying to spare healthy ones.
Bethesda, MarylandAges 18–120 - NCT06056921RecruitingPhase 1
CAR T-cell therapy for hard-to-treat autoimmune diseases
This trial tests a new treatment using your own immune cells (CAR T-cells) targeting a protein called CD19 to control severe autoimmune diseases like lupus, Sjogren's, scleroderma, dermatomyositis, or vasculitis. The goal is to see if it's safe and can improve symptoms when other treatments haven't worked.
Taiyuan, ShanxiAges 18 years+ - NCT06058234Recruiting
Tracking Alzheimer’s treatment for Medicare patients in early stages
This study tracks how well a certain type of Alzheimer’s treatment works for people on Medicare who are in the early stages of the disease. The goal is to collect real-world information about the drug’s benefits and risks.
Baltimore, MarylandAges Any age - NCT06071897RecruitingPhase 3
Chemo-immunotherapy for high-risk neuroblastoma
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
MoscowAges 1.5 years–18 years - NCT06090266RecruitingPhase 1/Phase 2
Study of OR502 alone and with other cancer treatments
This trial tests an experimental drug called OR502, which targets a protein on immune cells, to see if it can help fight advanced solid tumors. It is given alone or with other anti-cancer drugs, and the study aims to find the best dose and see how well it works.
Austin, TexasAges 18 years+ - NCT06102759Recruiting
Study of adebrelimab and fruquintinib plus chemo for advanced stomach cancer after PD-1 failure
This trial tests a combination of two targeted drugs (adebrelimab and fruquintinib) plus chemotherapy (paclitaxel or albumin-bound paclitaxel) for people with advanced gastric or gastroesophageal junction cancer whose disease progressed after prior PD-1 antibody treatment. The goal is to see if this new combination can help when standard options have stopped working.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06119685RecruitingPhase 1/Phase 2
IDP-023 alone or with other antibodies for blood cancers
This trial tests an experimental drug, IDP-023, given alone or with antibody therapies for people with advanced blood cancers like multiple myeloma or non-Hodgkin lymphoma that have not responded to previous treatments. The goal is to see if it can shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06121700RecruitingPhase 2
Chemoimmunotherapy and radiation before surgery for limited spread stomach cancer
This trial tests combining chemotherapy, immunotherapy, and radiation before surgery for stomach or gastroesophageal junction cancer that has spread to a limited number of sites. The goal is to see if this approach can improve outcomes by shrinking tumors before they are removed.
ShanghaiAges 18–75 - NCT06123884RecruitingPhase 2/Phase 3
BAT1308 plus chemotherapy for PD-L1-positive cervical cancer
This clinical trial tests a new combination therapy (BAT1308 plus chemotherapy, with or without Avastin) for women with advanced cervical cancer that is PD-L1-positive and has not been previously treated with systemic therapy. The goal is to see if this combination can shrink tumors or slow disease progression.
Wuhan, HubeiAges 18–70 - NCT06168032Recruiting
COVID-19 vaccine for lung cancer patients
This trial is testing how well the COVID-19 vaccine works for people with lung cancer to prevent another infection. It also looks at certain biomarkers in your blood that might help predict your body's immune response.
BeijingAges 18 years+ - NCT06170489RecruitingPhase 3
Study of JS004 plus toripalimab for Hodgkin lymphoma
This study tests a new combination of two drugs (JS004 plus toripalimab) versus standard chemotherapy for people with Hodgkin lymphoma that no longer responds to PD-1/PD-L1 immunotherapy. The goal is to see if the new combination works better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06170710RecruitingPhase 2
Immunotherapy after chemoradiation for high-risk head and neck cancer
This trial tests if adding immunotherapy after standard chemoradiation helps prevent cancer from returning in people with high-risk head and neck cancer. It is for those who have completed surgery and have certain high-risk features.
Beijing, Beijing MunicipalityAges 18–70 - NCT06177041RecruitingPhase 3
M108 plus chemo for CLDN18.2-positive stomach cancer
This trial tests a new drug (M108) combined with standard chemotherapy (CAPOX) as a first treatment for people with advanced stomach or gastroesophageal junction cancer that has a specific protein called Claudin 18.2. The goal is to see if adding M108 helps improve outcomes compared to chemotherapy alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT06182774RecruitingPhase 3
Fixed vs ongoing treatment for older adults with new myeloma
This trial compares stopping treatment after a set number of cycles versus continuing it for people over 65 or those who cannot have a stem cell transplant. It tests whether a fixed treatment period works as well as long-term treatment for newly diagnosed multiple myeloma.
Edmonton, AlbertaAges 18 years+ - NCT06203314Recruiting
Epstein-Barr virus and cancer risk study
This study looks at how Epstein-Barr virus (a common virus) may be linked to cancer risk. If you live in Zhongshan or Wuzhou City and are generally healthy, you may be able to join and help researchers learn more.
Zhongshan, GuangdongAges 30–69 - NCT06239727RecruitingPhase 3
Reduced-dose radiotherapy for stage III nasopharyngeal cancer based on response
This trial tests whether a lower dose of radiation can safely treat stage III nasopharyngeal cancer if you have already responded well to initial chemotherapy plus immunotherapy (Camrelizumab). The goal is to reduce side effects while still controlling the cancer.
Fuzhou, FujianAges 18–65 - NCT06255223RecruitingPhase 2
Radiation therapy plus immunotherapy for advanced kidney cancer
This trial tests a combination of targeted radiation therapy with a restart of immunotherapy for people whose kidney cancer has grown after prior immunotherapy. It aims to see if radiation can help the immune system fight the cancer again.
Nanjing, JiangsuAges 18–80 - NCT06274840Recruiting
COVID-19 antibodies in cystic fibrosis
This study looks at how the body makes antibodies (proteins that fight infection) against COVID-19 in people with cystic fibrosis. It helps doctors understand how well your immune system responds to the virus or vaccine.
LisbonAges Any age - NCT06280755Recruiting
AI-assisted MS care study
This study looks at how artificial intelligence (AI) can help doctors care for people with multiple sclerosis (MS) and other similar conditions. It uses existing medical data to see if AI can improve treatment decisions.
Prague, Praha 2Ages 18 years+ - NCT06308978RecruitingPhase 1
Study of FT819 for B-cell autoimmune diseases
This trial tests a new cell therapy, FT819, for people with certain autoimmune diseases like lupus, vasculitis, myositis, or scleroderma that haven't improved with at least two previous treatments. The goal is to see if it can help control the disease.
Beverly Hills, CaliforniaAges 12–70 - NCT06311214RecruitingPhase 2
Personalized ADC therapy for advanced solid tumors
This trial tests personalized antibody-drug conjugates (ADCs) for advanced solid tumors. It looks for specific proteins on your tumor cells to match you with a treatment that targets them directly.
Duarte, CaliforniaAges 18 years+ - NCT06311708Recruiting
PKP2-related heart condition natural history study
This study looks at how plakophilin 2 (PKP2)-related arrhythmogenic right ventricular cardiomyopathy (ARVC) progresses over time. You'll give blood samples to check for antibodies to a virus used in gene therapy, and help doctors understand the disease better.
San Francisco, CaliforniaAges 14–65 - NCT06316076RecruitingPhase 1
CD19 CAR-T cell therapy for autoimmune diseases
This trial tests a new type of immune cell therapy (CAR-T cells targeting CD19) for people with autoimmune diseases that haven't improved with standard treatments. The goal is to see if it is safe and can help control the disease.
ShanghaiAges 18–65
Hear when a new Antibody trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for antibody?
- Yes. Clin2 currently lists 539 recruiting antibody studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a antibody trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a antibody trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.